In this article, we want to explore Necitumumab and delve deeper into its different aspects and meanings. Necitumumab is a topic that has captured the attention of many people today and has generated great interest in society. Throughout this article, we will analyze different approaches and points of view on Necitumumab, as well as its importance in different contexts and areas of study. We will also examine its evolution over time and how it has impacted people's daily lives. In short, we will delve into the world of Necitumumab to understand its relevance and influence on modern society.
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | EGFR |
Clinical data | |
Trade names | Portrazza |
AHFS/Drugs.com | Multum Consumer Information |
License data |
|
Routes of administration | Intravenous infusion |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | ~14 days |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6436H9958N1702O2020S42 |
Molar mass | 144844.87 g·mol−1 |
(what is this?) (verify) |
Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR). The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC). It was counterproductive in non-squamous non-small-cell lung carcinoma.